The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disorders like melasma and post-inflammatory hyperpigmentation, and demand for advanced treatments such as laser therapy, chemical peels, and microneedling. North America leads the market, with the U.S. expected to reach $0.93 billion by 2035. Asia-Pacific is the fastest-growing region due to rising incomes and beauty consciousness. Key players include AbbVie, L'Oréal, and Johnson & Johnson.
AbbVie increased its quarterly dividend by 5.5% to $1.73 per share even as its flagship drug Humira faces steep revenue declines due to patent expirations. Despite Humira's sales dropping 36.1% in Q2 2026 and nearly 50% in 2025, AbbVie's strong free ...
AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, dr...
AbbVie announced positive Phase 3 results for etentamig, a BCMA x CD3 bispecific T-cell engager, in treating triple-class exposed relapsed/refractory multiple myeloma. The CERVINO study showed etentamig achieved a 74% objective response rate and a 60...
AbbVie has finalized its $10.9 billion acquisition of Apogee Therapeutics, enhancing its immunology portfolio with Apogee's late-stage drug candidates targeting inflammatory diseases like atopic dermatitis and asthma. Apogee's lead asset, zumilokibar...
AbbVie announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company's management will engage in a fireside chat at 9:00 a.m. Central time, which will be accessible via a live audio we...
